Vice President of Pharmacovigilance
Crescent Biopharma
Vice President of Pharmacovigilance
Crescent Biopharma
Clinical-stage biotech developing solid-tumor therapies
Salary Range: 323000 to 357000 (Currency: USD) (Pay period: per-year-salary)
We are seeking a strategic leader, Vice President of Pharmacovigilance to lead patient safety and pharmacovigilance needs, fostering a culture where safety is integrated into every aspect of our drug development process. This role may be based in a hybrid capacity from our Waltham, MA office or remotely from the East Coast. Reporting directly to the Chief Medical Officer (CMO), you will be leading and building out the Safety and PV. This includes being responsible for the strategic oversight and execution of all safety and pharmacovigilance activities, ensuring compliance with global regulatory standards.
As the VP, Head of Safety and Pharmacovigilance, you will lead our efforts in ensuring the safety of our investigational products. This involves providing strategic medical oversight, managing safety data, and guiding cross-functional collaboration to integrate safety into all phases of our product lifecycle. You will be responsible for creating and building the function. Your role will include interacting with regulatory authorities, leading the pharmacovigilance team, and overseeing the activities of external safety service providers. This role is based in Waltham, MA and you must have experience in the oncology space.
Clinical-stage biotech developing solid-tumor therapies
Crescent Biopharma develops oncology therapies for solid tumors, led by CR-001, a tetravalent bispecific antibody that blocks PD-1 and VEGF to boost anti-tumor immunity while inhibiting tumor blood vessel growth. CR-001 sits in a global Phase 1/2 ASCEND trial, and the pipeline also includes CR-002, an anti-PD-L1 antibody-drug conjugate, and CR-003, an ITGB6-targeted ADC. The company differentiates itself by combining immune checkpoint blockade with VEGF inhibition and other targeted modalities to build an immuno-oncology backbone for solid tumors, supported by strategic partnerships and substantial private placements. Crescent’s goal is to advance multi-agent regimens toward regulatory approval and commercial development for patients with solid tumors.
Explore more opportunities at Crescent Biopharma